IL32 and pulmonary arterial hypertension: Although this study retrospectively assessed a relatively low number of patients, the strong sensitivity and specificity observed in our work suggest that IL-32 sera levels may emerge as a new specific biomarker, helpful for an accurate screening of SSc patients with suspected WHO group 1 PAH, being our results a proof-of-concept to design further and powered studies to confirm and validate this result.